Raymond schreef op 5 augustus 2024 18:38:
Aug. 2, 2024, 06:33 AMIn a report released today, Jeff Jones from
Oppenheimer maintained a Buy rating on Pharming Group (PHAR – Research Report), with a
price target of $31.00. The company’s shares closed yesterday at $7.63.
According to TipRanks, Jones is a 4-star analyst with an average return of 8.3% and a 37.76% success rate. Jones covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Chemomab Therapeutics, and Corbus Pharmaceuticals.
Pharming Group has an analyst consensus of Moderate Buy, with a price target consensus of $34.00, a 345.61% upside from current levels. In a report released
yesterday (1 Augustus 2024), H.C. Wainwright also reiterated a Buy rating on the stock with a $37.00 price target.